Business

iMDx to Welcome Industry Veteran as Vice President of Medical Affairs to Prepare for Commercial Transplant Assay Launch

Dr. Nick Ioannou brings decades of academia, industry, and clinical experience in organ transplant, nephrology, cardiology, genetics, and oncology NASHVILLE, Tenn., Jan. 06, 2026 (GLOBE NEWSWIRE) -- Insight Molecular Diagnostics Inc., (Nasdaq: IMDX), or iMDx, today announced that it has appointed Dr. Nick Ioannou, M.D., MHA, to the position of Vice President, Medical Affairs. Dr. Ioannou is a physician-scientist with more than three decades of highly relevant experience spanning clinical practic

articleGuardant Health, Inc.January 6, 20263/company/guardant-health-inc/news/imdx-to-welcome-industry-veteran-as-vice-president-of-medical-affairs-to-prepare-for-commercial-transplant-assay-launch-1
iMDx to Welcome Industry Veteran as Vice President of Medical Affairs to Prepare for Commercial Transplant Assay Launch

About this update from Guardant Health, Inc.

[{"type":"image","alt":"Insight Molecular Diagnostics Inc.","displaySize":"","headline":null,"caption":"Insight Molecular Diagnostics Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":114,"url":"https://media.zenfs.com/en/globenewswire.com/0d7abfd3cc0e9f19d3f8615dce794ac4"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/a9omE9cBUejfoy9a_jJadQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTE2MDtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/0d7abfd3cc0e9f19d3f8615dce794ac4","width":300,"height":114}},"lazy":false},{"type":"list","items":[{"val":[{"type":"text","content":"Dr. Nick Ioannou brings decades of academia, industry, and clinical experience in organ transplant, nephrology, cardiology, genetics, and oncology","length":146,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":146,"olType":false},{"type":"text","content":"NASHVILLE, Tenn., Jan. 06, 2026 (GLOBE NEWSWIRE) -- Insight Molecular Diagnostics Inc., (Nasdaq: IMDX), or iMDx, today announced that it has appointed Dr. Nick Ioannou, M.D., MHA, to the position of Vice President, Medical Affairs.","length":231,"tagName":"p"},{"type":"text","content":"Dr. Ioannou is a physician-scientist with more than three decades of highly relevant experience spanning clinical practice, diagnostics, regulatory affairs, medical education, and medical affairs. His background includes over fifteen years of field-based collaboration with key opinion leaders across multiple therapeutic areas, particularly in organ transplantation, nephrology, cardiology, pulmonology, genetics, and oncology.","length":428,"tagName":"p"},{"type":"text","content":"He previously served Guardant Health as a senior staff medical science liaison and field director. Dr. Ioannou has also served in several other senior medical affairs positions, including as a medical science liaison for organ health and genetics at Natera, as director of medical education and medical communications at LA Ort Institute, as director of medical affairs at L-Nutra, and as international medical science liaison for heart and kidney transplant at CSL Behring. He has also held roles at Fresenius, Baxter, and Northwestern University, among others.","length":562,"tagName":"p"},{"type":"text","content":"Dr. Ioannou’s experience as a medical director and partner in private clinics for nearly 10 years has given him a keen a...

More updates from Guardant Health, Inc.

Dr. Nick Ioannouorgan transplantNick IoannouMedical AffairsMolecular Diagnosticsmedical communicationskidney transplanttransplant rejectionGuardant Healthmedical directorclinical experience